0001209191-22-061898.txt : 20221219 0001209191-22-061898.hdr.sgml : 20221219 20221219162033 ACCESSION NUMBER: 0001209191-22-061898 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221215 FILED AS OF DATE: 20221219 DATE AS OF CHANGE: 20221219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Seely Lynn CENTRAL INDEX KEY: 0001327111 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40502 FILM NUMBER: 221471342 MAIL ADDRESS: STREET 1: 501 2ND STREET STREET 2: SUITE 211 CITY: SAN FRANCISCO STATE: CA ZIP: 94107 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lyell Immunopharma, Inc. CENTRAL INDEX KEY: 0001806952 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 833006753 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 201 HASKINS WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650 695-0677 MAIL ADDRESS: STREET 1: 201 HASKINS WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-12-15 0 0001806952 Lyell Immunopharma, Inc. LYEL 0001327111 Seely Lynn C/O LYELL IMMUNOPHARMA, INC. 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 1 1 0 0 President and CEO Option (right to buy) 3.28 2022-12-15 4 A 0 7500000 0.00 A 2032-12-14 Common Stock 7500000 7500000 D Twenty-five (25) percent of the shares subject to the option shall vest on December 15, 2023 and 1/48th of the shares subject to the option shall vest in equal monthly installments thereafter until all shares are vested, subject to the reporting person remaining an employee of the Issuer on each applicable vesting date. /s/ Charles Newton, as Attorney-in-Fact 2022-12-19